Enzyme Plays Dual Tumor Suppressive Role in Kidney Cancer

Article

Researchers have identified a key gluconeogenic enzyme, the absence of which in clear cell renal cell carcinoma (RCC) may explain the uncontrolled cell growth present in cancer cells compared with normal kidney cells.

Image of primary human kidney tissue: FBP1 protein (green); cell nuclei (blue)

A metabolic enzyme has an unexpected role in regulating gene expression in kidney cancer. Image of primary human kidney tissue: FBP1 protein (green); cell nuclei (blue). Credit: Bo Li and Brian Keith, Perelman School of Medicine, University of Pennsylvania.

Researchers have identified a key gluconeogenic enzyme, the absence of which in clear cell renal cell carcinoma (RCC) may explain the uncontrolled cell growth present in cancer cells compared with normal kidney cells.

This discovery was made by Celeste Simon, PhD, professor of cell and developmental biology and scientific director of the Abramson Family Cancer Research Institute at the University of Pennsylvania, and colleagues, who published the results of their study in Nature.

Clear cell RCC is characterized by elevated glycogen and fat deposits in affected kidney cells. This over-storage of lipids is caused by a faulty series of biochemical reactions, called the Krebs cycle. Patients with clear cell RCC have a hyperactive Krebs cycle, resulting in enhanced lipid production. In addition, renal cancer cells are associated with both elevated expression of hypoxia inducible factors (HIFs) and mutations in the bon Hippel-Lindau (VHL) encoded protein, pVHL.

According to background information in the study, studies have shown that deletion of VHL alone did not produce clear cell RCC specific tumor formation in mice, suggesting that there may be additional mechanisms at play. Recent studies have shown that changes within the cell nucleus may account for kidney tumor progression.

Therefore, in their study, Simon and colleagues used pan-metabolic profiling and metabolic gene set analysis to analyze the metabolic enzymes in more than 600 tumor samples, and found that fructose-1,6-bisphosphatase 1 (FBP1), an enzyme essential for regulating metabolism, was depleted in almost 100% of the clear cell renal cell carcinoma samples.

“Notably, the human FBP1 locus resides on chromosome 9q22, the loss of which is associated with poor prognosis for clear cell RCC patients,” the researchers wrote.

Further study, showed that when FBP1 binds with HIF in normal cells, it suppressed clear cell RCC and other tumor cell growth. However, in cells with FBP1 depletion, the researchers observed the Warburg effect, a phenomenon in which malignant, rapidly growing tumors cells produced energy up to 200 times faster than normal cells.

Simon and colleagues also found that in cells deficient of pVHL, FBP1 restrained “cell proliferation, glycolysis and the pentose phosphate pathway in a catalytic-activity-independent manner, by inhibiting nuclear HIF function via direct interaction with the HIF inhibitory domain.” 

This unique dual function of FBP1 explains its ubiquitous loss in clear cell RCC, distinguishing FBP1 from previously identified tumor suppressors that are not consistently inhibited in all tumors.

“Collectively, our data reveal an intriguing regulatory relationship between FBP1 and hypoxic responses in renal carcinoma, which has implications for the metabolic regulation of all gluconeogenic tissues,” the researchers wrote.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content